These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31706717)

  • 1. Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma.
    Anderegg MCJ; Ruurda JP; Gisbertz SS; Blom RLGM; Sosef MN; Wijnhoven BPL; Hulshof MCCM; Bergman JJGHM; van Laarhoven HWM; van Berge Henegouwen MI
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):626-631. PubMed ID: 31706717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy.
    Kumagai K; Mariosa D; Tsai JA; Nilsson M; Ye W; Lundell L; Rouvelas I
    Dis Esophagus; 2016 Oct; 29(7):734-739. PubMed ID: 26316181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
    Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
    Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
    Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
    Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
    Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
    Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
    Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
    Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
    Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Unresectable T4b Esophageal Cancer: Practice Patterns and Outcomes From the National Cancer Data Base.
    Cushman TR; Shaaban SG; Moreno AC; Lin C; Verma V
    Am J Clin Oncol; 2019 Feb; 42(2):154-159. PubMed ID: 30499838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
    Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach.
    Suzuki G; Yamazaki H; Aibe N; Masui K; Sasaki N; Shimizu D; Kimoto T; Shiozaki A; Dohi O; Fujiwara H; Ishikawa T; Konishi H; Naito Y; Otsuji E; Yamada K
    Radiat Oncol; 2018 Dec; 13(1):246. PubMed ID: 30547811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?
    Markar S; Gronnier C; Duhamel A; Pasquer A; Théreaux J; du Rieu MC; Lefevre JH; Turner K; Luc G; Mariette C
    J Clin Oncol; 2015 Nov; 33(33):3866-73. PubMed ID: 26195702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
    Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
    Fu JH; Rong TH; Li XD; Hu Y; Ou W; Hu YH; Li Q
    Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.